P. Coluzzi

发表

Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.

L. Hart, M. Simmonds, R. Portenoy, 2001, Journal of pain and symptom management.

Cancer pain management: Newer perspectives on opioids and episodic pain

P. Coluzzi, 1998, The American journal of hospice & palliative care.

High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

J. Doroshow, L. Leong, S. Akman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.

M. Simmonds, R. Portenoy, M. Simmonds, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

Y. Yen, J. Doroshow, L. Leong, 1996, Cancer Chemotherapy and Pharmacology.

Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial

J. Doroshow, L. Leong, S. Akman, 1995, Journal of Cancer Research and Clinical Oncology.

The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies

N. Stambler, N. Slatkin, D. Brenner, 2021, Supportive Care in Cancer.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Y. Yen, J. Doroshow, L. Leong, 1998, Cancer research.

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus

D. Moore, S. Hurvitz, Xiaoyan Wang, 2020, Therapeutic advances in medical oncology.

Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.

J. Doroshow, L. Leong, G. Somlo, 1999, Gynecologic oncology.

Survey of the provision of supportive care services at National Cancer Institute-designated cancer centers.

L. Rivera, J. Doroshow, B. Ferrell, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.

J. Doroshow, L. Leong, S. Akman, 1995, Cancer investigation.

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

R. Portenoy, A. Lyss, R. Payne, 1999, PAIN.

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)

R. Portenoy, L. Schwartzberg, J. Ashley, 2001, Pain.

Lymphocyte receptors for polyclonal T mitogens. I. Concanavalin A binding to lymphocytes inhibits mitogenesis induced by galactose oxidase.

J. Parker, J. Favero, R. O'Brien, 1982, Cellular immunology.

A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

J. Horton, J. Goldman, E. Garon, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An institutional commitment to pain management.

B. Ferrell, G. Dean, M. Grant, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A

Y. Yen, J. Doroshow, L. Leong, 2000, Cancer Chemotherapy and Pharmacology.

Electroacupuncture for the management of symptom clusters in cancer patients and survivors (EAST)

M. Acharya, L. Torno, Keri B. Zabokrtsky, 2023, BMC Complementary Medicine and Therapies.

Sublingual morphine: efficacy reviewed.

P. Coluzzi, 1998, Journal of pain and symptom management.

Managing breakthrough pain. New method expands treatment options.

M. Rhiner, P. Coluzzi, 1998, Advance for nurse practitioners.

The management of pain in terminally ill cancer patients with difficulty swallowing

P. Coluzzi, Barbara Stock Fairbairn, Barbara Stock Fairbairn, 1999, The American journal of hospice & palliative care.

A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.

J. Goldman, E. Garon, C. Wells, 2018 .

Oral patient-controlled analgesia.

P. Coluzzi, 1997, Seminars in oncology.

MA 02.07 A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

J. Goldman, E. Garon, A. Lisberg, 2017 .

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

R. Portenoy, A. Lyss, R. Payne, 1999, PAIN.